Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Guida

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
Journal of Surgical Oncology|May 10, 2016
Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective studyMichele Guida, Luca G Campana, Pietro Curatolo, et al.
Molecular Cancer|January 19, 2022
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanomaSimona Serratì, Michele Guida, Roberta Di Fonte, et al.
Oncology Research|July 28, 2021
uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma CellsElena Andreucci, Anna Laurenzana, Silvia Peppicelli, et al.
Melanoma Research|July 18, 2006
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanomaMichele Guida, Angela Riccobon, Guido Biasco, et al.
Journal of Translational Medicine|January 28, 2015
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapyLetizia Porcelli, Gabriella Guida, Anna E Quatrale, et al.
Journal of Experimental & Clinical Cancer Research : CR|September 27, 2023
Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanomaSimona Serratì, Roberta Di Fonte, Letizia Porcelli, et al.
Cancers|October 17, 2019
The Management of Oligoprogression in the Landscape of New Therapies for Metastatic MelanomaMichele Guida, Nicola Bartolomeo, Ivana De Risi, et al.
BMC Cancer|May 12, 2018
The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)Michele Guida, Stefania Tommasi, Sabino Strippoli, et al.
Pharmacological Research|June 25, 2022
BRAF<sup>V600E;K601Q</sup> metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapyLetizia Porcelli, Roberta Di Fonte, Ciro L Pierri, et al.
Journal for Immunotherapy of Cancer|August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
Journal of Surgical Oncology|May 10, 2016
Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective studyMichele Guida, Luca G Campana, Pietro Curatolo, et al.
Molecular Cancer|January 19, 2022
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanomaSimona Serratì, Michele Guida, Roberta Di Fonte, et al.
Oncology Research|July 28, 2021
uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma CellsElena Andreucci, Anna Laurenzana, Silvia Peppicelli, et al.
Melanoma Research|July 18, 2006
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanomaMichele Guida, Angela Riccobon, Guido Biasco, et al.
Journal of Translational Medicine|January 28, 2015
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapyLetizia Porcelli, Gabriella Guida, Anna E Quatrale, et al.
Journal of Experimental & Clinical Cancer Research : CR|September 27, 2023
Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanomaSimona Serratì, Roberta Di Fonte, Letizia Porcelli, et al.
Cancers|October 17, 2019
The Management of Oligoprogression in the Landscape of New Therapies for Metastatic MelanomaMichele Guida, Nicola Bartolomeo, Ivana De Risi, et al.
BMC Cancer|May 12, 2018
The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)Michele Guida, Stefania Tommasi, Sabino Strippoli, et al.
Pharmacological Research|June 25, 2022
BRAF<sup>V600E;K601Q</sup> metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapyLetizia Porcelli, Roberta Di Fonte, Ciro L Pierri, et al.
Journal for Immunotherapy of Cancer|August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.
Pageof 13